Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy?
使用二肽基肽酶-4抑制劑調節巨噬細胞:治療糖尿病性心肌病的新前沿?
World J Diabetes 2024-09-16
Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease.
非酒精性脂肪肝病/代謝功能障礙相關脂肪肝病的新藥治療管道。
J Clin Transl Hepatol 2024-09-16
Effects of canagliflozin on kidney oxygenation evaluated using blood oxygenation level-dependent MRI in patients with type 2 diabetes.
canagliflozin 對於 2 型糖尿病患者腎臟氧合的影響,使用血氧水平依賴性 MRI 進行評估。
Front Endocrinol (Lausanne) 2024-09-16
Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.
基線特徵對於參與者使用每週一次皮下注射 semaglutide 治療 2 型糖尿病的療效影響:SUSTAIN China 的事後分析。
Diabetes Obes Metab 2024-09-16
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.
Cagrilintide 與臨床相關的 QTc 延長無關:在健康參與者中的徹底 QT 研究。
Diabetes Obes Metab 2024-09-16
O-linked β-N-acetylglucosamine (O-GlcNAc) modification: Emerging pathogenesis and a therapeutic target of diabetic nephropathy.
O-GlcNAc 修飾:糖尿病腎病的新興發病機制及治療靶點。
Diabet Med 2024-09-16
The impact of glucagon and exenatide on oxidative stress levels and antioxidative enzyme expression in in vitro induced steatosis in HepG2 cell culture.
胰高血糖素和exenatide對HepG2細胞培養中誘導的脂肪變性氧化壓力水平及抗氧化酶表達的影響。
Endokrynol Pol 2024-09-16
Role of oral hypoglycaemic drugs in preventing complication in non-alcoholic fatty liver disease with type 2 diabetes mellitus.
口服降血糖藥物在預防2型糖尿病合併非酒精性脂肪肝疾病併發症中的作用。
J Pak Med Assoc 2024-09-16